4.30
-0.03 (-0.69%)
| Previous Close | 4.33 |
| Open | 4.29 |
| Volume | 715,396 |
| Avg. Volume (3M) | 891,125 |
| Market Cap | 443,712,704 |
| Price / Sales | 13.85 |
| Price / Book | 0.990 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 |
| Operating Margin (TTM) | -583.86% |
| Diluted EPS (TTM) | -11.24 |
| Total Debt/Equity (MRQ) | 18.94% |
| Current Ratio (MRQ) | 3.73 |
| Operating Cash Flow (TTM) | -291.17 M |
| Levered Free Cash Flow (TTM) | -169.99 M |
| Return on Assets (TTM) | -101.07% |
| Return on Equity (TTM) | -247.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Alumis Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | 2.0 |
| Average | -0.25 |
|
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 53.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ayurmaya Capital Management Company, Lp | 31 Mar 2025 | 15,139,707 |
| Foresite Capital Management V, Llc | 31 Mar 2025 | 5,779,348 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (Morgan Stanley, 411.63%) | Buy |
| Median | 17.50 (306.98%) | |
| Low | 14.00 (HC Wainwright & Co., 225.58%) | Buy |
| Average | 17.75 (312.79%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 4.10 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 15 Aug 2025 | 22.00 (411.63%) | Buy | 4.75 |
| HC Wainwright & Co. | 14 Aug 2025 | 14.00 (225.58%) | Buy | 4.39 |
| 25 Jul 2025 | 14.00 (225.58%) | Buy | 3.88 | |
| Wells Fargo | 25 Jul 2025 | 17.00 (295.35%) | Buy | 3.88 |
| Guggenheim | 10 Jun 2025 | 18.00 (318.60%) | Buy | 3.36 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Aug 2025 | Announcement | Alumis to Participate in Upcoming September Investor Conferences |
| 13 Aug 2025 | Announcement | Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| 24 Jul 2025 | Announcement | Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus |
| 14 Jul 2025 | Announcement | Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |